Literature DB >> 19398861

Multiple cavernous hemangiomas of the skull associated with hepatic lesions. Case report.

Yasuo Sasagawa1, Takuya Akai, Kenji Yamamoto, Tooru Masuoka, Shoutarou Itou, Masahiro Oohashi, Hideaki Iizuka.   

Abstract

A 55-year-old woman presented with multiple calvarial cavernous hemangiomas manifesting as right frontal swelling. Craniography and computed tomography showed an osteolytic lesion. Magnetic resonance imaging demonstrated multiple intraosseous lesions, and radioisotope bone scintigraphy identified even more numerous lesions. Total resection of the right frontal lesion and cranioplasty was performed. Histological examination confirmed the lesion as a cavernous hemangioma. Computed tomography of the abdomen revealed multiple hepatic lesions, which might be cavernous hemangiomas. Cavernous hemangioma is a rare bony tumor that should be considered in the differential diagnosis of skull tumors. A patient with multiple cavernous hemangiomas should undergo systemic examination to look for latent lesions, and regular follow-up examinations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398861     DOI: 10.2176/nmc.49.162

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

1.  Intraosseous cavernous malformations of the skull: clinical characteristics and long-term surgical outcomes.

Authors:  Chengjun Wang; Dong Zhang; Shuo Wang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2018-10-17       Impact factor: 3.042

2.  Primary Intraosseous Cavernous Hemangioma in the Skull.

Authors:  Yi Yang; Jian Guan; Wenbin Ma; Yongning Li; Bing Xing; Zuyuan Ren; Changbao Su; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 3.  Multiple cavernous hemangiomas of the skull with dural tail sign: a case report and literature review.

Authors:  Peng Xu; Shengyong Lan; Youming Liang; Quan Xiao
Journal:  BMC Neurol       Date:  2013-10-25       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.